ClinicalTrials.gg
CompletedNCT06653374UCEUpdated Oct 22, 2024

Perinatal Conditions Influencing Morbidity, Mortality, and Medical Care in Newborns

An observational study in Preterm Birth, Low Birth Weight and Intrauterine Growth Restriction (IUGR), sponsored by HOSPITAL GINECO OBSTETRICO ISIDRO AYORA. Completed at 1 site in Ecuador. Open to participants aged Up to 28 Days. Per ClinicalTrials.gov, last updated 2024-10-22.

Sponsored by HOSPITAL GINECO OBSTETRICO ISIDRO AYORA · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
26,000
Ages
Up to 28 Days
Sex
All
01

Study summary

This study focuses on understanding the conditions that affect newborn health and survival from pregnancy to the first weeks of life at the Isidro Ayora Hospital. The investigators will review data from 2008 to 2022 to identify key factors that may contribute to complications, help improve medical care, and reduce risks for newborns. By doing so, we aim to provide better support to families, healthcare providers, and ensure safer births.

Read the detailed description

This research investigates the impact of various perinatal conditions-such as maternal health, prenatal complications, delivery methods, and neonatal management-on morbidity and mortality rates in newborns treated at the Isidro Ayora Obstetric-Gynecologic Hospital. Using a retrospective cohort design, the study analyzes data from 2008 to 2022 to identify patterns and correlations between perinatal factors and neonatal outcomes, aiming to inform evidence-based clinical practices and enhance neonatal care protocols.

Key aspects include evaluating the influence of gestational age, birth weight, maternal comorbidities (e.g., hypertension, diabetes), and obstetric complications on the health of neonates. Outcomes of interest include NICU admissions, length of hospital stay, and incidence of conditions such as respiratory distress syndrome, sepsis, and neonatal mortality. Findings will contribute to improving resource allocation, optimizing care strategies, and potentially guiding policy decisions to reduce adverse neonatal outcomes.

02

Conditions studied

  • Preterm Birth
  • Low Birth Weight
  • Intrauterine Growth Restriction (IUGR)
  • Perinatal Asphyxia
  • Neonatal Sepsis
  • Respiratory Distress Syndrome (RDS)
  • Neonatal Jaundice
  • Congenital Malformations
  • Neonatal Hypoglycemia
  • Gestational Diabetes Mellitus (GDM)
  • Placental Abruption
  • Preterm Premature Rupture of Membranes (PPROM)
  • Hypertension, Pregnancy-Induced
  • Pre-Eclampsia

Keywords

  • Infant, Premature
  • Infant, Low Birth Weight
  • Fetal Growth Retardation
  • Asphyxia Neonatorum
  • Sepsis, Neonatal
  • Respiratory Distress Syndrome, Newborn
  • Jaundice, Neonatal
  • Congenital Abnormalities
  • Hypoglycemia, Neonatal
  • Hypertension, Pregnancy-Induced
  • Diabetes, Gestational
  • Placental Abruption
  • Premature Rupture of Fetal Membranes
03

In context

Premature Birth

2,550 studies on the registry are indexed under Premature Birth; 500 are open to participants now.

This study's enrollment of 26,000 is above the median of 120 across 806 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

HOSPITAL GINECO OBSTETRICO ISIDRO AYORA is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population includes all live-born neonates delivered at the Isidro Ayora Obstetric-Gynecologic Hospital between January 2008 and December 2022. The cohort encompasses neonates born to mothers of diverse socioeconomic backgrounds, varying maternal health conditions, and different obstetric risk profiles. The study focuses on evaluating neonatal outcomes based on gestational age, birth weight, and the presence of perinatal complications, such as maternal hypertension, diabetes, or preterm labor. This population represents a high-risk group typical of a tertiary care referral center, allowing for a comprehensive analysis of factors influencing neonatal morbidity and mortality.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonates born at the Isidro Ayora Obstetric-Gynecologic Hospital between January 2008 and December 2022.
  • Live-born neonates with complete medical records in the hospital's perinatal database.
  • Neonates whose mothers received antenatal care and delivered at the hospital. Availability of maternal and neonatal data, including gestational age, birth weight, and outcome information.

Exclusion criteria

Exclusion Criteria:

  • Neonates with incomplete or missing medical records.
  • Neonates born outside the hospital and referred postnatally.
  • Stillbirths and pregnancies terminated due to maternal or fetal indications.
  • Neonates discharged to other facilities immediately after birth without follow-up data in the hospital\'s database.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
26,000 participants (actual)
Patient registry
No

Groups and cohorts

  • Infant, Premature

    The "Infant, Premature" group includes neonates born before 37 weeks of gestation at the Isidro Ayora Obstetric-Gynecologic Hospital. This cohort is particularly vulnerable to a range of complications, including respiratory distress syndrome, intraventricular hemorrhage, and infections, which are major contributors to neonatal morbidity and mortality.

    Behavioral: Infant, Premature

  • Neonatal Morbidity and Mortality Cohort

    This cohort includes all live-born neonates delivered at the Isidro Ayora Obstetric-Gynecologic Hospital between January 2008 and December 2022. The study focuses on evaluating the influence of various perinatal and neonatal conditions on morbidity and mortality outcomes. Interventions of interest include obstetric management strategies (e.g., use of antenatal corticosteroids, mode of delivery), neonatal resuscitation protocols, NICU admission criteria, and the implementation of specific neonatal care practices such as early surfactant administration, infection control measures, and nutritional support.

    Behavioral: Infant, Premature

Interventions

  • BehavioralInfant, Premature

    This intervention is distinct as it focuses specifically on observational monitoring and evaluation of neonatal outcomes without applying a therapeutic or procedural treatment. Unlike other interventional studies, the emphasis is on analyzing standard care practices, risk factor exposures (e.g., prematurity, maternal complications), and their impact on neonatal morbidity and mortality. The intervention involves systematic data collection and longitudinal follow-up to identify patterns and associations, rather than introducing new clinical techniques or treatment

06

What researchers measure

Primary outcomes

  1. Neonatal Mortality Rate

    The proportion of neonates who die within the first 28 days of life out of the total number of live births.

    Time frame: first 28 days of life

Secondary outcomes

  1. Neonatal Morbidity Incidence

    Incidence of major neonatal morbidities, including sepsis, respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, and perinatal asphyxia.

    Time frame: first 28 days of life

07

Study locations

1 site
  • Hospital Gineco Obstétrico Isidro Ayora
    Quito, Pichincha 170601, Ecuador
08

References and documents

Individual participant data

Plan to share: Undecided — The database contains sensitive information on neonates and their mothers, protected by ethical and confidentiality regulations. Due to the nature of the data and hospital policies, IPD will not be shared publicly to safeguard patient privacy and comply with local regulations. Aggregated results will be available in scientific publications, but individual data will not be accessible to third parties.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Sep 2024, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 22, 2024
StartActual
Nov 12, 2023
Primary completionActual
Sep 10, 2024
CompletionActual
Sep 10, 2024
Last update
Oct 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06653374
Lead sponsor
HOSPITAL GINECO OBSTETRICO ISIDRO AYORA
Collaborators
Universidad Central del Ecuador
Responsible party
Santiago Vasco-Morales (Principal Investigator, HOSPITAL GINECO OBSTETRICO ISIDRO AYORA) — Principal investigator
First posted
Oct 22, 2024
Start date
Nov 12, 2023
Primary completion
Sep 10, 2024
Completion
Sep 10, 2024
Last update
Oct 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion